Journal
JOURNAL OF CELL BIOLOGY
Volume 199, Issue 3, Pages 407-412Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1083/jcb.201208082
Keywords
-
Categories
Funding
- Danish National Advanced Technology Foundation [006-2005-1, 044-2007-1]
Ask authors/readers for more resources
MicroRNAs (miRNAs) are important post-transcriptional regulators of nearly every biological process in the cell and play key roles in the pathogenesis of human disease. As a result, there are many drug discovery programs that focus on developing miRNA-based therapeutics. The most advanced of these programs targets the liver-expressed miRNA-122 using the locked nucleic acid (LNA)-modified antisense oligonucleotide miravirsen. Here, we describe the discovery of miravirsen, which is currently in phase 2 clinical trials for treatment of hepatitis C virus (HCV) infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available